Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2059126 | 0.85 | GAA (0.35) | GAAMAPT | |
| Ethyne SCHEMBL5606123 | 0.68 | MAPT (0.47) | GAAMAPT | |
| SCHEMBL29398195 | 0.67 | — | — | |
| SCHEMBL3767165 | 0.67 | MAPT (0.53) | GAAMAPT | |
| SCHEMBL33554 | 0.67 | — | — | |
| SCHEMBL29418986 | 0.67 | MAPT (0.53) | GAAMAPT | |
| SCHEMBL29375766 | 0.67 | MAPT (0.53) | GAAMAPT | |
| SCHEMBL630372 | 0.67 | LMNA (0.31) | — | |
| SCHEMBL8984812 | 0.64 | — | — | |
| SCHEMBL28831762 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 585 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572384-B2 | Unusual substrates of tubulin tyrosine ligase | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2023-02-07 | — | — | US | claimed |
| US-20190144493-A1 | UNUSUAL SUBSTRATES OF TUBULIN TYROSINE LIGASE | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2019-05-16 | — | — | US | claimed |
| WO-2017186855-A1 | UNUSUAL SUBSTRATES OF TUBULIN TYROSINE LIGASE | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2017-11-02 | — | — | WO | claimed |
| EP-2423212-B1 | PROCESS FOR PRODUCTION OF 2-AZAADAMANTANE COMPOUND FROM BICYCLOCARBAMATE COMPOUND | NISSAN CHEMICAL IND LTD (JP) | 2016-06-01 | — | — | EP | claimed |
| CN-101321760-A | Pyrazolopyrimidines as protein kinase inhibitors | SCHERING CORP (US) | 2008-12-10 | — | — | CN | claimed |
| US-20080255144-A1 | Acylated Piperidines as Glycine Transporter Inhibitors | GLAXO GROUP LIMITED | 2008-10-16 | — | — | US | claimed |
| EP-1931676-A1 | PYRAZOLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2008-06-18 | — | — | EP | claimed |
| US-20080090822-A1 | Piperazine Derivatives As Glyt 1 Inhibitors | GLAXO GROUP LIMITED | 2008-04-17 | — | — | US | claimed |
| EP-1858869-A1 | ACYLATED PIPERIDINES AS GLYCINE TRANSPORTER INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-11-28 | — | — | EP | claimed |
| EP-1858868-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-11-28 | — | — | EP | claimed |
| EP-0564924-B1 | 2-Oxoethyl derivatives as immunosuppressants | BAYER AG (US) | 1998-09-09 | — | — | EP | claimed |
| EP-0825988-A1 | FUNGICIDAL CYCLIC AMIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1998-03-04 | — | — | EP | claimed |
| CN-1144526-A | Thiazolidines and oxazolidines substituted by pyridine ring and their use a hypoglycemic agents | NISSAN CHEMICAL IND LTD (JP) | 1997-03-05 | — | — | CN | claimed |
| EP-0751944-A1 | THIAZOLIDINES AND OXAZOLIDINES SUBSTITUTED BY A PYRIDINE RING AND THEIR USE AS HYPOGLYCEMIC AGENTS | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1997-01-08 | — | — | EP | claimed |
| WO-1996036616-A1 | FUNGICIDAL CYCLIC AMIDES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-11-21 | — | — | WO | claimed |
| CN-1134697-A | Pyrimidine-sulfanyl and alkyl ether compounds | UPJOHN CO (US) | 1996-10-30 | — | — | CN | claimed |
| WO-1995026347-A1 | THIAZOLIDINES AND OXAZOLIDINES SUBSTITUTED BY A PYRIDINE RING AND THEIR USE AS HYPOGLYCEMIC AGENTS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1995-10-05 | — | — | WO | claimed |
| EP-0564924-A2 | 2-Oxoethyl derivatives as immunosuppressants | Bayer Corporation (US) | 1993-10-13 | — | — | EP | claimed |
| EP-0523533-A1 | Substituted pyrimidin derivatives and their use for combatting the growth of undesirable plants | BASF Aktiengesellschaft (DE) | 1993-01-20 | — | — | EP | claimed |
| US-4851519-A | AMIDO NUCLEOSIDES, VIRICIDES | HOFFMANN-LA ROCHE INC. (US) | 1989-07-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255144-A1 | Acylated Piperidines as Glycine Transporter Inhibitors | SLC1A1, SLC6A7, SLC1A2 | GAA 729/4885MAPT 762/4885 |
| US-20080090822-A1 | Piperazine Derivatives As Glyt 1 Inhibitors | SLC6A7, SLC6A5, SLC1A2 | GAA 1245/4885MAPT 441/4885 |
| US-11572384-B2 | Unusual substrates of tubulin tyrosine ligase | TTL, TUBA1C, TUBB6 | GAA 2071/4885MAPT 696/4885 |
| US-20190144493-A1 | UNUSUAL SUBSTRATES OF TUBULIN TYROSINE LIGASE | TTL, TUBA1C, TUBB6 | GAA 2071/4885MAPT 696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.